Medication Guide App

Morton Grove Pharmaceuticals cleared to market prednisolone sodium phosphate oral solution

Morton Grove Pharmaceuticals cleared to market prednisolone sodium phosphate oral solution

MORTON GROVE, ILL., October 12, 2004 -- Morton Grove Pharmaceuticals announced that the FDA had cleared for market Prednisolone Sodium Phosphate Oral Solution, 15mg/ 5ml. It will treat asthma and other inflammatory conditions in children.
 
According to the FDA approval letter dated 17 September 2004, Morton Grove Pharmaceuticals' Prednisolone Sodium Phosphate Oral Solution, 15mg(base)/ 5ml is bioequivalent and therefore therapeutically equivalent to Orapred Oral Solution, 15mg(base)/ 5ml of Ascent Pediatrics, Inc.

Frank Stiefel, Vice President of Sales and Marketing, said, "We are very excited about this approval. Our researchers have exceeded expectations by developing a formulation that is pharmaceutically unique and convenient for patients. Not only has our product been rated therapeutically equivalent to Orapred, it offers the added benefit of not requiring refrigeration."

Source: Morton Grove Pharmaceuticals

Posted: October 2004


View comments

Hide
(web1)